Clumping factor A (ClfA) (ClfA)

Clumping factor A (ClfA) is a major cell-surface protein and virulence factor of Staphylococcus aureus, belonging to the MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) family [1, 2]. Its primary biological function is to mediate bacterial adhesion to host tissues by specifically binding to the C-terminal region of the human fibrinogen gamma-chain [1, 14]. This interaction facilitates the formation of bacterial clumps, promotes platelet aggregation, and allows the pathogen to colonize medical devices and damaged endovascular surfaces [1, 6, 14]. Beyond adhesion, ClfA plays a significant role in immune evasion by inhibiting opsonophagocytosis and interfering with the complement system [1, 11]. In clinical contexts, ClfA is a major driver of serious infections such as infective endocarditis, sepsis, and septic arthritis [1, 13]. Therapeutic strategies targeting ClfA include monoclonal antibodies like tefibazumab and multivalent vaccines such as Pfizer's SA4Ag, which aim to block fibrinogen binding and enhance bacterial clearance [2, 25, 34]. These interventions are designed to disrupt the early stages of infection and prevent the establishment of biofilms [2, 6]. However, challenges such as sequence variability among S. aureus strains and the functional redundancy of other staphylococcal adhesins have complicated the development of highly effective anti-ClfA therapies [3, 8, 12]. Despite these challenges, ClfA remains a high-priority target for the development of novel immunotherapies against antibiotic-resistant S. aureus [33].

Other names

Fibrinogen receptor AFibrinogen-binding protein AMSCRAMM ClfAFibrinogen-binding proteinRecombinant clumping factor A

Inhibition of fibrinogen binding, prevention of bacterial attachment and colonization, enhancement of opsonophagocytosis, and neutralization of virulence factors.